Subscribe to European Biotechnology Magazine’s news feed.
Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: European Biotechnology Magazine
Is this your feed? Claim it!
French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business. Sevasemten, the centerpiece of the deal, has failed its pivotal trial in Becker muscular dystrophy, despite encouraging results from earlier studies.
The post
As advanced therapies and vaccines reshape healthcare, Wacker Biotech is emerging as a CDMO partner of choice. With decades of experience and integrated expertise spanning pDNA, RNA, LNP formulation, GMP production, and targeted LNP conjugation, the company offers end-to-end support to accelerate cell and gene therapies, RNA-based medicines, and next-generation vaccines fro...
Swedish biotech BioArctic has lost a partnership with Swiss drugmaker Novartis to develop a potential treatment for neurodegenerative diseases using its BrainTransporter technology. The termination eliminates the prospect of up to $772 million (€691 million) in additional payments, although BioArctic retains the $30 million (€27 million) upfront payment.
The post
Denmark-based BioInnovation Institute (BII) is expanding its European CardioMetabolic Bridge to Munich and Berlin. Backed by up to DKK 450 million (around €60 million) from the Novo Nordisk Foundation, the initiative aims to accelerate the translation of academic research into metabolic and cardiovascular diseases into drug development and biotech companies. Following the est...
AstraZeneca is cutting costs and early cancer programs, while Ayrmid is pursuing another struggling U.S. drugmaker. This week’s six updates also include a Huntington’s gene therapy review, mixed MS data and new plans for vaccines and hypertension treatment.
The post